SuperworthCardiff Oncology EPS CRDF
Diluted earnings per share by quarter and over the last twelve months, from 2011.
- Last 12 months, to Jun 30, 2026
- −$0.60
- Latest quarter, Q2 FY26
- −$0.14
- Fiscal year 2025
- −$0.69
Cardiff Oncology's earnings per share was −$0.60 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.14.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.69 | n/a |
| FY2024 | −$0.95 | n/a |
| FY2023 | −$0.93 | n/a |
| FY2022 | −$0.89 | n/a |
| FY2021 | −$0.71 | n/a |
| FY2020 | −$1.30 | n/a |
| FY2019 | −$2.98 | n/a |
| FY2018 | −$13.69 | n/a |
| FY2017 | −$54.54 | n/a |
| FY2016 | −$99.36 | n/a |
| FY2015 | −$88.56 | n/a |
| FY2014 | −$62.64 | n/a |
| FY2013 | −$51.12 | n/a |
| FY2012 | −$62.64 | n/a |
| FY2011 | −$16.56 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.14 | n/a | −$0.60 | |
| Q1 FY26 | −$0.18 | n/a | −$0.67 | |
| Q4 FY25 | −$0.11 | n/a | −$0.69 | |
| Q3 FY25 | −$0.17 | n/a | −$0.80 | |
| Q2 FY25 | −$0.21 | n/a | −$0.88 | |
| Q1 FY25 | −$0.20 | n/a | −$0.93 | |
| Q4 FY24 | −$0.22 | n/a | −$0.95 | |
| Q3 FY24 | −$0.25 | n/a | −$0.94 | |
| Q2 FY24 | −$0.26 | n/a | −$0.91 | |
| Q1 FY24 | −$0.22 | n/a | −$0.90 | |
| Q4 FY23 | −$0.21 | n/a | −$0.93 | |
| Q3 FY23 | −$0.22 | n/a | −$0.92 |
Against its peers
Companies in Healthcare nearest Cardiff Oncology's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CRDFCardiff Oncology | −$0.60 | |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NEPHNephros | $0.16 | +33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cardiff Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.